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We have previously identified a family of novel an-
drogen receptor (AR) ligands that, upon binding,
enable AR to adopt structures distinct from that
observed in the presence of canonical agonists. In
this report, we describe the use of these com-
pounds to establish a relationship between AR
structure and biological activity with a view to de-
fining a rational approach with which to identify
useful selective AR modulators. To this end, we
used combinatorial peptide phage display coupled
with molecular dynamic structure analysis to iden-
tify the surfaces on AR that are exposed specifi-
cally in the presence of selected AR ligands. Sub-
sequently, we used a DNA microarray analysis to
demonstrate that differently conformed receptors
facilitate distinct patterns of gene expression in
LNCaP cells. Interestingly, we observed a com-
plete overlap in the identity of genes expressed
after treatment with mechanistically distinct AR
ligands. However, it was differences in the kinetics
of gene regulation that distinguished these com-
pounds. Follow-up studies, in cell-based assays of
AR action, confirmed the importance of these al-
terations in gene expression. Together, these stud-
ies demonstrate an important link between AR
structure, gene expression, and biological out-
come. This relationship provides a firm underpin-
ning for mechanism-based screens aimed at iden-
tifying SARMs with useful clinical profiles.
(Molecular Endocrinology 20: 1201–1217, 2006)
STEROID HORMONE receptors are ligand-depen-dent transcription factors involved in the regula-
tion of a wide range of physiological processes rang-
ing from reproduction to cellular metabolism and
homeostasis. In addition, inappropriate production of
steroids or a change in the way the steroid-receptor
(SR) complex is recognized by target cells underlies
the pathology of many diseases. Not surprisingly,
therefore, agents that positively or negatively regulate
the action of this class of receptors have found wide-
spread clinical use in the treatment of a diverse range
of endocrinopathies. For the most part, the need for
agonists and antagonists for each member of this
receptor family has been satisfied by the currently
available compounds/drugs. Consequently, attention
has shifted toward the exploitation of our current un-
derstanding of SR action to develop compounds,
whose actions at their cognate receptors allow their
activities to be manifest in a tissue- and process-
selective manner.
In general terms, the cellular response to a given
steroid hormone can be considered a composite of
both its genomic and nongenomic activities. The latter
describes the rapid responses to steroid-occupied re-
ceptors observed in vitro that result in the activation or
modulation of cell signaling pathways (i.e. MAPK) (1,
2). The mechanism(s) and physiological importance of
these nongenomic pathways are poorly understood,
and as yet compounds that activate these processes
at the expense of the better characterized genomic
responses have not been developed. Considerably
more is known about the mechanism(s) by which the
genomic actions of SRs are manifest. Specifically, it
has been determined that the ligand-free receptor is
maintained in an inactive state in the absence of ligand
through its association with a large heat shock protein
(HSP) complex within the cytoplasm of target cells.
Upon binding a ligand, the receptor undergoes a con-
formational change permitting the displacement of the
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HSP complex. This is followed by spontaneous recep-
tor dimerization, nuclear translocation, and the subse-
quent interaction of the receptor dimer with the regu-
latory regions of target gene promoters. When
occupied by an agonist, the promoter-bound receptor
then recruits, in succession, functionally different
classes of transcription coactivators that together ef-
fect a change in chromatin structure and enhance
target gene expression. In the presence of an antag-
onist, the binding of corepressors to the SR is favored,
and target gene expression is decreased (3). Based on
these mechanistic insights, it is now believed that the
cellular response to a specific SR ligand is determined
by 1) the relative expression level in cells of receptor
subtypes and isoforms; 2) the effect of the bound
ligand on the overall shape of the receptor; 3) the
effect of the adopted shape on cofactor recruitment; 4)
the relative and absolute expression levels of individ-
ual cofactors in specific tissues; and 5) the activity of
signaling pathways that impinge on the receptor-li-
gand complex (4–6). Much of this insight has come
from the study of estrogen receptor (ER) pharmacol-
ogy, where an explanation for the tissue selective ag-
onist/antagonist activities of the selective ER modula-
tor (SERM) tamoxifen was sought. Indeed, fueled by
the clinical and commercial success of SERMs, there
is now a heightened level of interest in using the in-
sights obtained from the study of these compounds to
develop tissue/process selective modulators of other
members of this receptor family. The current study is
aimed at defining aspects of the androgen receptor
(AR) signal transduction pathway that are important in
determining the pharmacological actions of andro-
gens and how these may be exploited to develop
selective AR modulators (SARMs).
Previous studies that have attempted to link the
conformation of the AR-ligand complex and its phar-
macological properties have focused mostly on the
role of the interaction between the N- and C-terminal
domains of AR (7–9). This approach was based largely
on work that indicated that AR agonists, but not an-
tagonists, are able to facilitate an interaction between
the F/WXXLF motifs in the N-terminal domain of AR
and the activation function (AF)-2 coactivator binding
pocket located in the C-terminal ligand-binding do-
main (8, 10). Emerging from these studies was the
tenet that an interaction between these domains was
an obligate feature of AR agonists. However, it is the
exception to this general rule that holds the most
promise for the development of SARMs. Specifically, it
has been observed that casodex and mifepristone
(RU486), previously defined as AR antagonists, and
partial agonists such as cyproterone acetate and me-
droxyprogesterone acetate, are unable to induce AR
N-/C-terminal interactions, yet they exhibit various de-
grees of agonist activity in cell-based transcription
assays (8, 11–13). It now appears more likely that
N-/C-terminal interactions are involved primarily in the
regulation of AR turnover and in determining agonist
potency as a consequence of their ability to stabilize
ligand binding (13, 14). Thus, it remains to be deter-
mined how AR antagonists and partial agonists man-
ifest agonist activity in some, but not all, cell and
promoter contexts. We propose that AR partial ago-
nists (SARMs) may function, as SERMs do on ER, by
altering receptor structure in such a manner as to
engender differential coactivator interactions, and that
coactivator availability and activity determine ligand
efficacy.
To test the SARM hypothesis, we sought to capital-
ize on the observation that the partial agonist activity
of RU486 was mechanistically distinguishable from
that exhibited by canonical AR agonists. In a previous
report from our laboratory, we described the synthesis
and characterization of compounds, Research Trian-
gle Institute (RTI)-6413-018 (RTI-018) and RTI-6413-
001 (RTI-001), which are similar in structure to RU486
but do not support AR N-/C-terminal interactions. How-
ever, these compounds possess full agonist activity in
proliferation assays and display various degrees of ago-
nist activity on classical androgen-responsive promoters
(15). In the current study, we have built on these initial
observations to probe the relationship between the con-
formation of AR induced by these compounds and their
ability to regulate differential gene expression in prostate
cancer cells. In thismanner, we anticipated that we could
test the SARM hypothesis and provide the mechanistic
underpinning for screens to identify AR modulators with
useful clinical properties.
RESULTS
Peptide Profiling Reveals Ligand-Dependent
Changes in AR Structure
In the past, we have been able to monitor ligand-
induced changes in ER structure using combinatorial
peptide phage display, and we have used this tech-
nique to identify surfaces whose presentation is re-
lated specifically to the occupancy of the receptor by
a specific ligand. Using this strategy, we sought to
determine whether the distinct biological activities of
RTI-001 and RTI-018 were related to their ability to
induce distinct conformational changes in AR struc-
ture. A complete description of the phage display
screening strategy that we have used has been de-
scribed elsewhere (16). After affinity selection, the in-
serts of all phage that interacted with AR-RTI-001 in a
specific manner were expressed as GAL4-DNA bind-
ing domain fusions and assessed for their ability to
interact with a full-length wild-type (wt) AR-VP16 pro-
tein in a mammalian two-hybrid assay. The results of
this assay, using three of the most informative pep-
tides identified, are shown in Fig. 1A. The sequences
of the peptides used in these experiments are shown
in Table 1. Notably, all three peptides interact to a
significant degree with AR in the absence of ligand and
in the presence of antagonist Casodex. Treatment of
cells with either RTI-001 or RTI-018, but not with ago-
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Fig. 1. Binding of Affinity-Selected Peptides and Known Cofactors to AR Liganded with Canonical Agonists and the SARM
Compounds
Mammalian two-hybrid analysis was performed in HepG2 cells transfected with VP16-AR and peptide or cofactor fragments
fused to Gal4-DBD as indicated. After 20 h, cells were treated in triplicates with hormones as indicated for 40 h. The peptide or
cofactor interaction with the receptor was assayed using a luciferase reporter gene regulated by five copies of the GAL4-
responsive element. Luciferase activity was normalized to -galactosidase activity derived from the pCMV-Gal vector included
with all transfections. A, Binding of the peptides selected in the presence of RTI-6413-001 to wt and T877A AR. pM, Gal4-DBD
alone without peptide as negative control. B, Binding of the peptides selected in the presence of R1881. EH peptides were
identified by Hur et al. (17). The sequence of the NTD peptide is derived from the sequence of human AR (CAI43080). C and D,
Binding of fragments of known cofactors ARA54 (361–474 fragment) and C-terminal domain of NCoR (amino acids 1944–2453)
to wt and T877A AR. The data in panels C and D are plotted as a ratio of the (VP16-AR/pM-cofactor) specific signal to the
(VP16-AR/pM control) background. CASX, Casodex.
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nists 5--dihydrotestosterone (DHT) or R1881, facili-
tates this interaction. Because the peptides were se-
lected using RTI-001-liganded AR as a target, it was
not surprising that some were found to bind with less
avidity to the RTI-018-occupied receptor in mamma-
lian two-hybrid assays. We also noted that the inter-
action of these peptides with AR in the presence of
SARMs depends on the presence of both N-terminal
domain and ligand binding domain (LBD) because nei-
ther of these domains is able to recruit these peptides
(data not shown). Interestingly, the canonical agonists
DHT and R1881 discouraged the binding of these
peptides to AR. Although the screening was per-
formed using wt AR as a target, we have demon-
strated in Fig. 1A that the selected peptides display
the same binding characteristics when assessed on
the T877A AR, the receptor mutant expressed in
LNCaP cells. For these studies, we also created ad-
ditional GAL4 peptide fusions using the AR AF-2 in-
teracting FXXLF-containing peptides identified re-
cently by Hur et al. (17) using phage display of DHT-
activated AR LBD. For comparative purposes, we also
evaluated a similarly sized peptide fragment contain-
ing the native FXXLF derived from the N-terminal do-
main of AR, which is responsible for the intra- or
intermolecular interaction of the AR amino and car-
boxyl termini. As expected, all of these FXXLF-con-
taining peptides interact with AR in mammalian two-
hybrid screens in the presence of either DHT or R1881
(Fig. 1B). However, the binding patterns observed in
the presence of the two SARMs are quite distinct. In
the case of EH1, EH2, and EH5, for instance, both
SARMs function like the antagonist casodex. The pep-
tides EH6, EH7, and N-terminal domain (NTD), on the
other hand, are able to interact, at least partially, with
AR in the presence of RTI-018. The inability of RTI-001
to facilitate these interactions provides compelling ev-
idence that the structures of AR in the presence of
these SARMs are similar but distinct. These peptides
interact with T877A AR in an identical fashion (not
shown).
The peptide profiling assays revealed distinct struc-
tural changes in AR associated with the binding of
different ligands. However, because of the complexity
of the peptide libraries we have generated exceeds
that of the human genome, it was unclear whether the
conformational differences induced by these ligands
would be sufficient to elicit differential cofactor inter-
actions. To address this issue, we again turned to the
mammalian two-hybrid assay and evaluated the inter-
action of AR with the receptor-interacting domains of
validated AR-cofactors. Given the fact that the best
characterized cell culture-based model of prostate
carcinoma, LNCaP, bears a mutation in AR LBD
(T877A), we also tested whether this mutation affects
the recognition of these cofactors in the mammalian
two-hybrid assay. It became evident from these stud-
ies that both SARMs stimulate the recruitment of the
FXXLF-containing fragment of ARA54 to AR, although
we reproducibly observe a more robust interaction
with the RTI-018-activated receptor (Fig. 1C). In con-
trast, the binding of the receptor interacting domain of
the corepressor nuclear receptor corepressor (NCoR)
was only observed in the presence of RTI-001 (Fig.
1D). Interaction of both coactivator and corepressor
fragments with AR was dependent on the presence of
the N-terminal domain because we could not detect
any interaction with AR LBD (AR 624–919) alone (data
not shown). We believe that this represents an inherent
instability in the LBD of AR rather than an indication
that the amino terminus of the receptor contributes
directly to the peptide binding surface. Importantly, we
did not observe any differences in the recruitment of
these two cofactors in the presence of different li-
gands between wt and T877A AR. Given these data, it
is reasonable to expect that DHT- and SARM-acti-
vated AR will have overlapping, though distinct, bio-
logical activities and similarly, that in some biological
systems RTI-001 and RTI-018 will be distinguishable.
Ligand-Regulated Changes in AF-2 Architecture
Recent crystallographic studies have provided consid-
erable insight into the mechanisms by which coacti-
vator peptides interact with the AR AF-2 when the
receptor is occupied by an agonist (17, 18). The key
residues involved in the formation of the peptide bind-
ing site are illustrated in Fig. 2A. Given the peptide and
cofactor binding data, and the N-/C-terminal interac-
tion data, we hypothesized that the SARMs RTI-001
and RTI-018 may alter the conformation of the AF-2
pocket in a manner distinguishable from that observed
Table 1. The Sequences of Peptides Used in the Mapping of the AR Surfaces in the Presence of SARMs
Peptide Name Type Sequence Reference
1132–4 LXXLL LQMWEKYLPALLTMDDHVV This report
1232–6 CoRNR YYLSQWHLRGNIYDKISTVPTPS
1332–4 X6-P-X6 LFHLRYPWLWDME
NTD FXXLF SKTYRGAFQNLFQSVREVI hAR (CAI43080)
EH1 FXXLF SSRFESLFAGEKESR (17)
EH2 FXXLW SSKFAALWDPPKLSR
EH5 FXXYF SSNTPRFKEYFMQSR
EH6 FXXFF SRFADFFRNEGLSGSR
EH7 LXXLL SSRGLLWDLLTKDSR
Constrained residues in peptides 1132–4, 1232–6, and 1332–4 are underlined. hAR, Human AR.
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Fig. 2. Computed Structural Alterations within the AF-2 Site upon SARM Binding
A, The structure of the AR AF-2 (1I37) site, showing the key residues involved in the formation of the peptide-interacting
surfaces. B, Solvent-exposed area of AF-2 (coactivator peptide binding site) pocket. Residues included in surface area calcu-
lations: L712, V716, W718, M734, I737, W747, M894, M895, I898. The numbers below the structures show the calculated
solvent-accessible area of AF-2 in both wt and T877A AR variants. WT (wt) structures shown. C and D, Predicted repositioning
of the helix 12 in the wt and T877A AR in the presence of DHT, RTI-018, and RTI-001. C, Calculated positions of H12 in the wt
(purple ribbon) and T877A (red ribbon) in the presence of RTI-018. Position of H12 in the presence of DHT (wt AR) is shown in
translucent gray. D, Calculated position of the H12 in wt and T877A AR in the presence of RTI-001. Color coding is the same as
in panel C. RTI ligands are shown and color coded as follows: in the context of wt AR, green; in T877A AR, yellow. Position of
Ser 778 is shown in panel C and color coded the same as ligand.
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in the presence of DHT. As a first step in testing this
hypothesis, we performed a molecular dynamics (MD)
simulation of AR complexed with the RTI ligands and
DHT and compared the resulting structures. Because
LNCaP cells, which were used for a number of exper-
iments presented in this manuscript, express the
T877A AR mutant with altered ligand specificity, we
used both wt and T877A structures for molecular
modeling experiments. For the MD simulations, the
initial relative positions of the RTI-001 and RTI-018
ligands were generated by superimposing the steroid
core of the RTI ligands over the steroid core of DHT,
followed by removal of the DHT molecule. The struc-
tures with DHT, RTI-018, and RTI-001 were then min-
imized and equilibrated. MD simulations were per-
formed for 1 nsec. After equilibration, MD trajectories
were analyzed for the conformational differences be-
tween DHT- and SARM-bound receptor.
One important indication of a conformational
change in AF-2 is the modification of the solvent ac-
cessible area of the residues that comprise the AF-2
pocket. Thus, solvent accessible areas were calcu-
lated for the hydrophobic residues in the AF-2 pocket
and averaged over MD trajectory snapshots. The re-
sults of this analysis indicate that the solvent acces-
sible area of the AF-2 pocket on the surface of the
receptor is larger in the presence of RTI-018 than in
the presence of DHT, and is even larger in the pres-
ence of RTI-001 (Fig. 2B). We extended these analyses
to quantitatively estimate the observed alterations in
the AF-2 shape. To do this, we measured the dis-
tances between pairs of residues (C atoms) that pre-
viously have been shown to form the pocket that can
accommodate the 1, 4, and 5 residues of an
FXXLF motif in the simulated structures of AR LBD in
complex with DHT or SARMs. The measurements,
averaged over the MD trajectory, are shown in Table 2.
In these estimations, we assumed that the distances
between 1) M734-K720 defines the size of 5 pocket,
2) I737-V716 and I737-L712 define the size of the 5
and 4 pockets, 3) I737-I898, and I737-M894 are
related to the size of 1 pocket, and I737-E897 and
K720-E897 define the relative positions of the charge
clamp residues of AF-2. It becomes evident from Table
2 that in the AR (both wt and T877A)-RTI-018 complex
the conformation of AF-2 is similar to that in AR-DHT
complex, with the exception of the 4 to 1 region in
wtAR-RTI-018 complex, which is described by the
I737-L712 distance. This distortion may be responsi-
ble in part for the observed lower transcriptional ac-
tivity of wtAR-RTI-018 compared with T877A AR-RTI-
018 in transfected cells (data not shown) because it
was found to differ significantly between the two re-
ceptors (12 Å vs. 9.9 Å). It should be noted that we
observed an increase of predicted distances between
all residues in H12 and corresponding reckoning
points elsewhere in AF-2 in T877A AR-DHT vs. wtAR-
DHT, indicating a possible lateral shift of H12 in the
mutant AR by approximately 1.5 Å. However, wt and
T877A ARs demonstrate equal ability to activate tran-
scription with DHT in transfected cells (data not
shown).
The largest distortion observed within the AF-2
pocket occurs upon binding RTI-001 and is located in
the area that accommodates the 1 residue in the
coactivator peptides. Specifically, we observed that
the distance between the charge clamp residues K720
and E897 increases dramatically in the case of both wt
and T877A AR (by 4.3 and 3.4 Å, respectively). The
distances describing the shape of 1 pocket and the
configuration of H12 were also calculated to be sub-
stantially different in RTI-001 complexes compared
with DHT. This indicates a possible change in the
position and shape of H12 and is different from the
alteration predicted for the RTI-018 complex. Also, it
becomes apparent from Table 2 that the shape of H12
is altered differently in wt and T877A-RTI-001 com-
plexes (I737-M894 distance).
The model presented in Fig. 2, C and D, represents
the predicted conformations of H12 in the presence of
the RTI ligands in both wt and T877A contexts. The
chemical structures of the ligands are shown in Sup-
plemental Fig. 1, which is published as supplemental
data on The Endocrine Society’s Journals Online web
site at http://mend.endojournals.org. As can be seen,
RTI-018 causes little change in the position of H12, in
both wt and mutant receptors (Fig. 2C). In both cases,
its configuration was predicted to be similar to that of
the AR-DHT complex. In the case of RTI-001, the
configuration of H12 is altered dramatically, for both
wt and mutant AR. The differences between the struc-
tures of AR-SARM complexes are determined by the
Table 2. Interatomic Distances (Å) between the Key Residues in the AF-2 Pocket of AR as Measured for the MD Trajectory
Snapshots and the Original DHT-AR Structure 1I37 (27)
Residues
DHT RTI-6413-018 RTI-6413-001
WT T877A WT T877A WT T877A
Met734-Lys720 10.5 11.2 10.05 11.1 12.0 10.1
Ile737-Leu712 9.1 9.2 12.02 9.9 9.1 9.9
Ile737-Val716 5.9 5.8 5.8 6.5 7.3 5.7
Ile737-Ile898 8.15 10.0 9.5 11.0 12.8 16.0
Ile737-Met894 12.6 13.9 12.3 13.0 10.4 16.1
Ile737-Glu897 12.5 14.0 12.6 14.5 14.3 15.5
Lys720-Glu897 18.9 20.0 19.5 21.2 23.2 23.4
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positioning of the ligand within the ligand-binding
pocket. In the wt context, the RTI ligands are predicted
to make a hydrogen bond between 17-acetyl and the
T877, in a manner similar to DHT. This allows the
anchoring of the 17-position and the fixation of the
steroid core in the ligand-binding pocket in a position
similar to that of DHT. In the mutant AR context, how-
ever, this hydrogen bond to the steroid core is absent,
which allows for the drift of the ligand within the
pocket. However, in the case of RTI-018, this drift is
limited due to the predicted hydrogen bond between
the hydroxyl group of the 17--propan-3-ol and the
backbone oxygen of serine 778. As a result, the RTI-
018 ligand is predicted to assume a position in which
the bulky 11 substituent is positioned away from the
helix 12 and is not making physical contact with it. This
allows for the preservation of the agonist-like confor-
mation of the helix 12. However, the positioning of the
11-p-acetylphenyl in the wt receptor was observed
to be in a closer proximity to helix 12, causing a partial
degradation of its native structure, which may be re-
sponsible for the lower efficacy of RTI-018 on wt AR in
transfected cells (Fig. 2C and Supplemental Fig. 2).
RTI-001, unlike RTI-018, features the 17 substituent
that is unable to form a hydrogen bond. In the wt
context, this ligand is predicted to form a hydrogen
bond with T877 through the 17 acetyl oxygen, which
results in the direct physical contact between its 11-
dimethylaniline group and the base of helix 12. This
results in the unwinding of the proximal region of helix
12, and substantial changes to the structure of AF-2,
which involve M895, M896, and charge clamp residue
E897 (Fig. 2D). In the T877A context, the hydrogen
bond that fixes the 17-position of the steroid core is
absent, which allows for the shift of the ligand mole-
cule within the ligand binding pocket. The predicted
new position of the RTI-001 ligand places the 11
substituent on the opposite side of the base of the
helix 12, but still in direct contact with it. The resulting
structural alterations in the Helix 12 in the T877A con-
text are different from those observed in the wt recep-
tor. The main differences are that, unlike the wt recep-
tor, for which the largest distortions were observed in
the proximal region of the helix, in the T877A, we
observed a planar shift of the entire helix 12 away from
AF-2 pocket (Fig. 2D). This results in the increased
distances between the charge clamp residues and is
predicted to negatively affect the transcriptional activ-
ity of the receptor.
We conclude from these findings that the subtle
change in the substituents at the 11 and 17 posi-
tions has a dramatic impact on the structure of the
AF-2 and coactivator peptide binding preferences. In-
tuitively, these structural rearrangements would be
predicted to have an immediate impact on the trans-
activation properties of these compounds, making
RTI-001 a weaker agonist than RTI-018 and DHT. As
will be shown in the next section, these predictions
were borne out when the functional properties of these
ligands were compared in relevant models of AR
action.
Linking Ligand-Induced Changes in AR Structure
to Differences in Gene Expression Profiles
A key step in proving the SARM hypothesis relies on
the ability to establish a link between AR structure,
gene expression, and specific biological activities. To
achieve this, we chose to use Affymetrix Gene Chip
technology (Santa Clara, CA) to survey genome-wide
changes in AR-dependent gene transcription in the
presence of different ligands in LNCaP cells. For these
initial studies, we compared DHT- and RTI-018-
induced changes in mRNA levels after 6 and 24 h of
hormone treatment. We also performed independent
follow-up experiments where the activities of RTI-018
and RTI-001 on a select number of genes were com-
pared. To establish a baseline, we used the profiles
observed in cells treated with vehicle alone. Using a
mixed linear statistical model on the log2 perfect-
match data along with a Bonferroni correction to con-
trol the probability of one or more false positives at
0.05, a total of 1433 significantly changed genes and
expressed sequence tags (ESTs) were identified on
the Affymetrix HU133 A chip, and an additional 296
were detected on the B chip. A cluster analysis of the
significantly altered genes revealed two major expres-
sion profiles, the characteristics of which are de-
scribed in detail below (Fig. 3). The first class (cluster
1), which contains 747 genes and ESTs, includes
those genes whose transcription is repressed by an-
drogens. For the majority of these genes, transcrip-
tional repression became evident at 6 h and continued
for 24 h or more. Interestingly, for most of these genes
maximal repression by DHT was evident at 6 h, with
little additional repression occurring in the subsequent
18 h. However, in the presence of RTI-018, transcrip-
tional repression increased over time, so that by 24 h
the magnitude of repression became significantly
greater than that observed with DHT treatment. For
some genes from this cluster, however, both DHT and
RTI-018 displayed nearly equal efficacy of repression
at 24 h. Examples of both kinds of regulation of genes
from this group are presented in Fig. 4 and include the
3-hydroxymethylglutaryl coenzyme A (CoA) synthase
2 (HMGCS2, NP_005509) and the ATP-dependent
transporter G (ABCG1, NP_004906). The ability of the
antagonist casodex to inhibit RTI-mediated repression
confirmed that this repression is AR dependent.
Most of the AR-responsive genes identified were
positively regulated to some degree by DHT and both
SARMs (Cluster 2; Fig. 3). These genes fell into two
groups: 1) those whose expression was up-regulated
at an early time point (6 h), and 2) genes that were
up-regulated at a later (24 h) time point, whereas lower
or no induction was observed at 6 h time point. Two
genes from this class, SLC16A6 (NP_004685) and Kal-
likrein-3 (PSA, NP_001639), were selected for a more
complete analysis (Fig. 5). Both were significantly in-
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duced by DHT and RTI-018, but the latter compound
demonstrated lower efficacy and potency. However,
overall analysis of the 388 genes from this cluster on
the HG-Hu133-A chip suggests that, on average, RTI-
018 acts as full agonist at 0.1 M. When analyzed in a
similar manner, RTI-001 functioned as a weaker partial
agonist. The agonist activity of all three compounds
was attenuated by inclusion of the antiandrogen ca-
sodex. Casodex shows little inhibition at 6 h, which
could be partially enhanced by preincubation of cells
with casodex before the addition of hormones. How-
ever, the improvement is not significant, which is in
agreement with the notion that casodex acts as a
low-affinity competitive antagonist (Supplemental Fig.
3, A–C). As can be seen in Fig. 5, A and B, and in Fig.
3, some genes demonstrate a right shift in DHT po-
tency between 6 and 24 h. The magnitude of the loss
of potency of DHT varies depending on the cell pas-
sage and other as yet unknown factors. DHT does not
inhibit gene activation by RTI-018 at 24 h, which ex-
cludes the possibility of the conversion of DHT into an
antagonistic derivative as a reason for the loss of
potency of DHT response over time (Supplemental
Fig. 4). We cannot exclude the possibility, however,
that this right shift is caused by degradation of DHT
into inactive metabolites. This, however, seems un-
likely, given the fact that hundreds of genes show
response at 24 h to DHT. It would appear, therefore, as
if members of this class of genes are under some type
of negative feedback control that alters sensitivity to
hormones, and that the RTI-SARMs do not induce this
activity. Currently, we are trying to define the molecular
mechanism(s) that regulate ligand potency and/or kinet-
ics of activation on these genes. Cycloheximide inhibi-
tion studies revealed that most of the tested genes re-
quire continuous protein synthesis for expression (data
not shown). Therefore, it cannot be excluded that even
for the down-regulated genes, the primary effect of an-
drogens is up-regulation of an upstream effector. Inter-
estingly, we observed a 100% overlap between the
Fig. 3. Hierarchical Clustering Analysis of DHT and RTI-6413-018-Regulated Genes in LNCaP Cells
Clustering analysis of 1430 significant genes and ESTs on chip A, and 297 significant genes and ESTs on chip B (Affymetrix
Hu.133 chip set) is shown. Red and blue depict deviations in normalized, standardized mean intensity from the average intensity
across the treatment conditions, up and down, respectively. Two major groups of genes showing common regulatory behavior
are indicated: cluster 1 (Cl.1), down-regulated by androgens; cluster 2 (Cl.2), up-regulated.
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spectra of DHT- and SARM-regulated genes. The differ-
ences between compounds, therefore, lie not in the al-
tered promoter specificity, but in altered kinetics of the
response. A more complete list of the representative
genes from each cluster is presented in Supplemental
Table 1. The Affymetrix pivot tables are included in the
supplemental materials.
In summary, our peptide profiling and modeling
studies predicated that DHT and the chosen SARMs
should be biologically distinguishable, a finding that
was borne out in the analysis of the gene expression
profiles in cells treated with these compounds.
Classification of the Regulated Genes
Although the gene array data provided important end-
points with which to study and classify androgens, we
also wished to determine whether there is an associ-
ation between the classes of regulated genes and
specific biological responses. To achieve this, we ex-
panded our studies to use standard annotation algo-
rithms for the androgen-regulated genes from the
three classes described above. We performed a gene
ontology analysis using the 960 regulated unique
genes with known functions that we identified in our
array studies. The assignments arrived at from this
study are as follows, the numbers in brackets indicat-
ing the number of genes assigned to each category: 1)
cell cycle control [30], 2) DNA metabolism [36], 3)
cellular metabolism [76], 4) cell maintenance and ho-
meostasis [221], 5) signal transduction [97], 6) regula-
tion of apoptosis [14], 7) mitochondrial maintenance
and energy metabolism [36], and 8) transcription fac-
Fig. 4. Real-Time RT-PCR Analysis of the Dose-Response Patterns of Two Representative Genes that Are Down-Regulated by
Both DHT and RTI-6413-018
ABCG1 and HMGCS2 genes are shown. Both genes appear to be more strongly repressed by RTI-018 and RTI-001 than by
DHT. Error bars show SEM. Casodex was used at 1 M. The hormone plus casodex points shown correspond to 10 nM hormone
competed with 100 molar excess of casodex. N/H, No hormone.
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tors [68]. A total of 578 genes were assigned to one of
the above categories. Next we assessed the distribu-
tion of genes from each gene ontology group among
the main classes of coregulated genes identified in our
analysis above (Fig. 6). Considering all of the genes
identified, it is apparent that each class of regulated
genes (down-regulated, early up-regulated, and late
up-regulated) is represented to a similar degree (lower
right panel). Likewise, each class is represented to the
same degree among genes associated with mitochon-
drial biogenesis and function, cell maintenance, and
regulation of apoptosis. It is noticeable, however, that
a significant number of genes involved in metabolism,
cell cycle control, and DNA metabolism, belong to the
class of late up-regulated genes. Indeed, 61% of
genes involved in metabolism, 67% in the control of
cell cycle group, and 80% in the DNA metabolism
group are up-regulated at the late (24 h) time point. In
contrast, genes from this class are underrepresented
in the transcription factors and signal transduction
groups, comprising only 19% and 7% respectively
(Fig. 6). Interestingly, in these groups, it is class 1, the
down-regulated genes, which are represented most
frequently. It should be noted that part of the observed
pattern of gene regulation could be attributed to the
T877A mutation in LNCaP AR, which alters ligand
specificity, or to other cellular factors specific to this
cell line. Similar studies performed in prostate carci-
noma LAPC4 cells, which harbors wt AR, demon-
strated a significantly different pattern of regulation of
representative genes from each class (Supplemental
Fig. 5).
Different Physiological Pathways Are
Differentially Regulated by the Candidate SARMs
and Canonical Agonists
It is clear from the studies presented above that RTI
compounds do not act simply as partial agonists but
display differences in the gene activation kinetics.
Fig. 5. Real-Time RT-PCR Analysis of the Time- and Dose-Response Patterns of Two Representative Genes that Are Up-
Regulated by DHT and SARMs.
SLC16A6 and PSA (KLK3) are shown. Consistent with the placement of these genes in the hierarchical clustering analysis,
SLC16A6 shows transient up-regulation by DHT and more prolonged up-regulation by SARMs. PSA (prostate-specific antigen),
similar to other genes from its cluster (late up-regulated) shows dramatic increase in mRNA level between 6 and 24 h. Error bars,
SEM. Casodex was used at 1 M. N/H, No hormone.
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Therefore, we became interested in testing whether
this altered kinetics of gene activation results in differ-
ential regulation of physiological pathways which are
known to be regulated by androgens. The two easily
measured endpoints of androgen action in LNCaP
cells are proliferation and accumulation of lipids in the
cytoplasm (19). As reporter earlier, the RTI SARMs act
as full agonists in proliferation assays (Fig. 7B). We
therefore wished to test whether they would have the
same or a different effect on lipogenesis. In the mi-
croarray analysis of the androgen- and SARM-respon-
sive genes, we had also detected a number of genes
Fig. 6. Gene Ontology Classification of the Known Androgen- and SARM-Regulated Genes
The 578 of 960 regulated genes with known functions were classified according to their gene ontology annotation terms as
indicated. Within each gene ontology group, genes were classified according to their regulation pattern. The lower right panel
shows the distribution of all 578 genes among the three major regulation pattern groups.
Kazmin et al. • Structure-Function Relationship for AR Mol Endocrinol, June 2006, 20(6):1201–1217 1211
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 05 May 2015. at 16:11 For personal use only. No other uses without permission. . All rights reserved.
that are involved in lipid metabolism, such as lipopro-
tein lipase, low-density lipoprotein receptor, insulin-
induced gene 1, stearoyl-CoA desaturase 9, stearoyl-
CoA desaturase 5, ABCG1, emapomyl binding
protein, DHCR24 (Seladin-1), fatty aldehyde dehydro-
genase, carnitine O-ocanoyl transferase, HMG-CoA
reductase, HMG-CoA synthases 1 and 2, fatty acid
synthase, and others. Most, but not all, of these genes
belong to the class of late up-regulated genes, and are
induced by both DHT and SARMs, with SARMs acting
as full or partial agonists. Fatty aldehyde dehydroge-
nase and carnitine O-ocanoyl transferase belong to
the class of early up-regulated genes, whereas
ABCG1 and HMGCS1 belong to class 1 (late down-
regulated). Most of these genes show a pattern of
regulation by SARMs different from that by DHT. We
Fig. 7. Accumulation of Neutral Lipids in LNCaP Cells in Response to Androgen Treatment
A, Increased lipogenesis in LNCaP in response to androgens. Lipid accumulation over 72 h was measured by Oil Red O
inclusion as described in Materials and Methods, and normalized to the total cell number. Casodex was used at 1 M. B,
Proliferation of LNCaP cells in the presence of SARM compounds. For proliferation assays, LNCaP cells were seeded at 80,000
cells per well in 24-well clusters and allowed to attach and spread for 3 d in medium containing dextran-charcoal filtered serum
to reduce hormone background. Hormones were added on d 4 and the medium was refreshed on d 6 and 8. Cell growth was
assayed on d 10 by DPA assay (36). N/H, No hormone.
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assessed the net effect of the coordinated expression
of these and other genes involved in the regulation of
lipid metabolism by measuring the lipid content of
LNCaP cells after treatment with the canonical ago-
nists and the RTI compounds. Surprisingly, accumu-
lation of neutral lipids in the presence of either SARM
is minimal compared with that observed in the pres-
ence of the nonmetabolizable AR agonist R1881 (Fig.
7A). Measurable accumulation is observed only at
concentrations above 10 nM, and even at micromolar
concentrations there is only minimal production of lip-
ids. This is in contrast to the high efficacy of these
compounds in proliferation assays, where they stimu-
late proliferation as well as canonical AR agonists.
These results indicate that candidate SARM com-
pounds are able to differentially regulate distinct phys-
iological pathways in LNCaP cells. Given the moderate
sensitivity of lipid accumulation to the inhibition by
casodex, it remains to be determined whether the
lipogenesis in LNCaP cells is mediated solely through
AR, or there is an involvement of other nuclear recep-
tors, such as PPAR.
DISCUSSION
With the development of SERMs and their successful
introduction into the clinic, there has been a high level
of interest in exploring the possibility of developing
selective modulators of other ligand-regulated nuclear
receptors. In this regard, it is clear that tissue- or
process-specific modulators of the progesterone re-
ceptor, glucocorticoid receptor, and AR would have
tremendous clinical utility. Examples would be selec-
tive progesterone receptor modulators that separate
activities in the breast and uterus; selective glucocor-
ticoid receptor modulators by which the metabolic,
osteopenic, and antiinflammatory activities could be
separated; and finally SARMs that separate the ana-
bolic action of classical androgens from their negative
effects on prostate, central nervous system, and lipids.
Although the advent of SERMs provided the impetus
to embark on a search for modulators of these recep-
tors, it has until recently been unclear how this could
be accomplished. The discovery of SERMs was fortu-
itous in that the first member of this class, tamoxifen,
was initially characterized as an ER antagonist but was
subsequently found to have antiresorptive activities in
bone (20). The second SERM raloxifene (formerly
known as keoxifene) was also developed as an ER
antagonist but differed from tamoxifen in that it did not
display uterotrophic activity (21–23). Although these
SERMs were discovered serendipitously, the subse-
quent insight into their mechanism of action has led to
the development of more SERMs and selective mod-
ulators of other nuclear receptors. Specifically, it has
become clear that different ligands have different ef-
fects on ER structure and that these differences have
distinct biological consequences (24). It was within the
framework of this understanding that we began our
study on the development of SARMs. Here we present
the demonstration that: 1) AR structure is influenced
by the nature of the bound ligand; 2) the conforma-
tional changes observed are likely to be important
as they lead to the presentation of different protein-
protein interaction surfaces; 3) these conformational
changes track with differential regulation of gene ex-
pression; and 4) with specific biological activities. The
ability to alter AR structure and thus effect different
biological responses raises expectations that andro-
gens with favorably dissociated activities with clinical
utility will be identified.
The candidate SARM compounds used in our stud-
ies are all derived from the core structure of RU486, a
drug with demonstrated AR partial agonist activity
(12). This compound belongs to a class of nuclear
receptor antagonists that contain a bulky side chain at
the 11 position that functions by displacing helix 12 in
the coactivator binding pocket of the LBD of the re-
ceptors with which it interacts (25). We introduced
changes into the structure of RU486 and assessed the
impact of these changes on the conformation of AR
and the resulting impact on downstream biology. In-
terestingly, we discovered that a simple replacement
of a 17 hydroxyl group in RU486 with an acetyl moi-
ety (RTI-6413-001) leads to increased proliferative ac-
tivity in LNCaP cells, which is likely to have resulted
from the increase in ligand affinity (Fig. 7B). Impor-
tantly, the transcriptional agonist activity of the result-
ing compound remains low in reporter assays and
in assays where the transcription of endogenously
expressed AR-responsive genes was assessed. The
replacement of the 11-p-dimethylaniline and 17-
prop-1-yne groups with 11-p-acetylphenyl and 17-
propan-3-ol moieties yielded the compound RTI-018.
Like RTI-001, this compound functions as a full ago-
nist in proliferation assays, and a partial agonist in
cell-based transcription assays. It should be noted
that the agonist activity of these compounds, both in
proliferation and transcription assays, occurs in the
absence of a detectable N-/C-terminal interaction.
Similar characteristics were reported for a series of
11-alkyl analogs of RU486 in which the length of the
alkyl side chain was correlated with AR affinity, inhibi-
tion of N-C interaction, and partial agonist activity. Of
interest, one of these compounds, 11-pentyl-9-19-
nortestosterone, does not support N-/C-terminal in-
teraction, potently inhibits N-/C-terminal interaction
induced by DHT, and shows appreciable partial ago-
nist activity with IC50 in subnanomolar range and effi-
cacy over 50% that of DHT (11). Together, these find-
ings indicate that significant agonist activity of AR
ligands can occur in the absence of a classical AF-2
coactivator-interacting pocket.
A central tenet of the SARM hypothesis is that it will
be possible to modify AR structure with small mole-
cules and that in doing so the genetic program regu-
lated by this receptor can be modified. Our studies
with the RTI compounds reveal that the gene expres-
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sion profiles overlap considerably with those of a clas-
sical AR agonist, although very significant differences
in the kinetics of target gene induction were noted.
Using combinatorial peptide phage display and mo-
lecular modeling, we have been able to demonstrate
that these differences in response may be correlated
to specific changes in AR structure in and around the
AF-2 region of the receptor. We interpret these data to
mean either that different surfaces are presented on
the receptor upon binding different ligands, or that
there are functionally important changes in a single
pocket afforded by different compounds. The obser-
vation that the RTI peptides (Fig. 1A), but not those
containing an FXXLF motif, can bind to an AR mutant
in which helix 12 is removed (data not shown) sug-
gests that the two classes of peptides interact with the
receptor in a different manner. Furthermore, deletion
of the AR amino terminus also compromises the bind-
ing of the RTI-specific, but not the FXXLF-containing
peptides, implying that the interaction surface of the
latter peptides is complex, requiring contributions
from outside of the ligand binding pocket (data not
shown). In accord with these findings, MD simulation
experiments revealed large-scale alterations in AR
structure upon binding of RTI-018 and RTI-001, which
involve sites distal to the previously defined AF-2 do-
main (not shown). The findings of our studies under-
score the importance of defining the cofactors/pro-
teins that interact with AR in the presence of the RTI
compounds, with a view to establishing a link between
the structure of the AR-ligand complex, cofactor re-
cruitment, and the regulation of gene expression. Al-
though these studies are underway, the preliminary
studies looking at recruitment of ARA54 and NCoR
using a mammalian two-hybrid system indicate that
the conformational changes we have observed do in-
deed translate into differential cofactor recruitment.
The molecular modeling approach presented here
has its own limitations, such as that it cannot account
for the contribution of the N-terminal portion to the
stabilization of ligand- and peptide binding. Our stud-
ies indicate that this stabilization is important, as the
deletion of NTD and DNA binding domain (DBD) neg-
atively affects the binding of peptides presented in Fig.
1A, as well as ARA54 and NCoR fragments (data not
shown). However, in the absence of the crystal struc-
ture of full-length AR, isolated LBD provides the best
model for predicting the conformational change di-
rected by novel ligands.
Our studies provide evidence that the biological
consequence of SARM action may not require abso-
lute changes in gene expression but occur as a result
of differences in the kinetics of induction of similar
genes. Indeed, the SARMs studied here either exag-
gerate the effects of DHT on some genes (most down-
regulated), or cause up-regulation of the expression of
some genes with altered time-course (most early up-
regulated), or work as partial to full agonists (late up-
regulated). In agreement with these observations, the
RTI SARMs have an impact on the same physiological
pathways as canonical agonists but recapitulate the
different facets of DHT action: strong stimulation of
proliferation, similar to that caused by DHT at its most
active concentration (1 nM; Fig. 7B) but weaker stim-
ulation of lipogenesis.
It is now well accepted that ligand-induced alter-
ations in ER structure are at the root of SERM action.
However, to our knowledge, the studies presented
here are the first to demonstrate that differential acti-
vation of androgen-responsive gene transcription can
be accomplished using small molecules that regulate
the presentation of different protein-protein interaction
surfaces on AR. Thus, although the identification of the
first generation of SERMs occurred in an empirical
manner without an understanding of the relationship
between ER structure and biological activity, the de-
velopment of SARMs is likely to occur in a more ra-
tional manner. This study, therefore, establishes a firm
link between AR structure and differential gene regu-
lation; a first step in the establishment of mechanism-
based screens for SARM identification.
MATERIALS AND METHODS
Affinity Selection of AR-Binding Sequences
Baculovirus-expressed full-length wt AR expressed in the
presence of RTI-6413-001 was purified as described in (26).
For panning, the purified receptor was diluted in 100 l of
NaHCO3 (pH 8.5), applied to a single well in a 96-well Costar
plate (Corning Inc. Life Sciences, Acton, MA), and incubated
at 4 C overnight. The wells were blocked with 150 l of 2%
nonfat dry milk in NaHCO3 for an additional 1 h at room
temperature and washed five times with PBST [137 mM NaCl,
2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4 (pH 7.3), 0.1%
Tween 20] to remove excess protein. Then 25 l of the phage
peptide library (with 1010 phage particles) diluted in 125 l
of PBST with 106 M hormones and 2% milk was added to
the wells, and the plate was sealed and incubated for 3 h at
room temperature. Nonbinding phage were removed by
washing the wells five times with PBST. The bound phage
were eluted with 100 l of 0.1 M HCl and neutralized with 100
l of 100 mM Tris-HCl (pH 8.0). Phage eluted from the targets
were amplified in Escherichia coli DH5F cells for 5 h, and
the supernatant containing amplified phage was collected for
use in subsequent rounds of panning. A total of four rounds
of panning were performed. Enrichment of AR binding phage
was confirmed by enzyme-linked immunosorbent assay. In-
dividual phage were PCR amplified after the third panning,
and shotgun cloned into pMsx vector for use in mammalian
two-hybrid assay. The libraries used were constrained in the
following way: X7-L-X-X-L-L-X7 (library 11, peptide 1132–4,
Fig. 1A); X7-L-X-X-H/I-I-X-X-X-I/L-X7 (library 12, peptide
1232–6 on Fig. 1A); X6-P-X6 (library 13, peptide 1332–4, Fig.
1A). “X” designates any amino acid, encoded by a random
NNK codon. Library construction is described in (16).
Mammalian Two-Hybrid Assay
HepG2 hepatocellular carcinoma cells were seeded in 24-
well plates at approximately 100,000 cells per well in MEM
supplemented with 8% fetal bovine serum, nonessential
amino acids and sodium pyruvate. Cells were transfected
using the lipofectin reagent (Invitrogen) in OPTI-MEMwith the
combination of expression constructs for full-length AR (wt or
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T877A)-VP16 fusion or AR LBD (AR 624–919) (wt or T877A)-
VP16 fusion, or VP16 control (1000 ng), cofactor-GAL4DBD
fusion or GAL4DBD control (1000 ng), reporter construct
(5Gal4-Luc3, 900 ng) and CMV-Gal expression construct
for normalization of transfection efficiency (100 ng). All plas-
mid quantities provided are per three wells. After 20 h, cells
were washed with PBS and exposed to 107 M of hormones
as indicated or ethanol vehicle in MEM supplemented with
8% charcoal-stripped fetal bovine serum with additional sup-
plements, as above for 40 h. Interaction of AR and cofactors
was assessed by measuring luciferase activity in cell lysates
and normalizing it to Gal activity. Mammalian two-hybrid
experiments that tested peptide binding to AR were per-
formed in a similar manner in HepG2 cells. In this case, AR
was expressed as a VP16 fusion, and the peptides as
GAL4DBD fusions.
Molecular Modeling
MD simulations were performed for the AR occupied by DHT,
RTI-6413-018, or RTI-6413-001. The initial geometries for
simulations were provided by crystal structure 1I37 from the
Protein Data Bank (27). For modeling of the T877A complex,
T877 in 1I37 structure was replaced with alanine, and the
resulting structure was energy minimized and equilibrated. All
calculations were performed with the Amber 8.0 program (28)
using the force field for protein described by Cornell et al. (29,
30), and General force fields (31) for the ligands. Hydrogen
atoms were added to the structure using standard amino acid
geometries as templates. Partial charges on the ligand mol-
ecules were fitted by using Merz-Singh-Kollman method (32,
33). The structures of AR with DHT, RTI-6413-018, and RTI-
6413-001 bound were solvated by placing them into a box of
TIP3P water molecules. Two thousand steps of steepest
descent and 3000 steps of conjugated gradient minimization
were performed. Periodic boundary and constant pressure
conditions were used. Molecules were equilibrated with 2.5
nsec MD simulation, and 500 psec productive MD trajecto-
ries were analyzed using PTRAJ (34) and HARLEM programs
(HARLEM, Molecular Modeling Package, http://www.
kurnikov.org/harlem_main.html.)
DNA Microarray Experimental Design
LNCaP cells were grown in DMEM/8% fetal bovine serum
supplemented with sodium pyruvate and nonessential amino
acids in T75 flasks to approximately 70% confluence. The
cells were washed with PBS three times, and the medium
was replaced with phenol red-free DMEM/8% charcoal-
stripped fetal bovine serum with the above supplements.
After 3 d, the medium was replaced with the same medium
supplemented with 108 M DHT or 107 M RTI-6413-018 or
ethanol vehicle. Cells were harvested by trypsinization at 6
and 24 h and immediately frozen in liquid nitrogen. Three
flasks were used per treatment, per time point, and conse-
quently pooled to account for possible flask-to-flask varia-
tions. mRNA was isolated using the Oligotex midi kit (QIA-
GEN, Valencia, CA). Hybridizations were performed on the
Affymetrix Hu.133AB platform. Vehicle-treated samples were
exposed for the same time periods as the hormone-treated
samples and used as controls. Three biological replicates
were used for each treated condition.
Statistical Analysis of the Microarray Data
The analyses were performed using probe-level data. The
probe intensities were extracted from CEL files by utilizing the
Affymetrix Input Engine from the SAS Microarray Solution
software (SAS Institute Inc.). A logarithm based 2 transfor-
mation was applied to the raw perfect-match intensities.
Upon inspection of the scatter plots of pairs of chips within a
replicated group, some curvature was observed (Supplemen-
tal Fig. 6). To normalize this nonlinear relationship between
chips, a LOESS adjustment was applied. The normalization
process was performed by running LOESS Normalization
from the SAS Microarray Solution with smoothing parameter
equal to 0.5. This procedure uses the mean intensities across
all chips as common baseline, and fits the data from each
chip to this baseline. The LOESS-normalized intensities equal
the corresponding intensities of baseline plus the corre-
sponding residual from the LOESS fit. Supplemental Fig. 6
represents the scatter plots between two replicated chips
before and after normalization, respectively. After normaliza-
tion, the following mixed model was applied by running
Mixed Model Analysis from the SAS Microarray Solution.
Refer to Ref. 35 for details on applying mixed models to
probe-level data.
Y ijkl	C iT jCT ijP lCP ilTP jlAk ijkl
Ak
N0, 2a
 ijkl,
N0, 2
Here, Y represents the normalized data. C, T, and P represent
the treatment condition, time, and probe effects, respec-
tively. The composite symbols represent the interactions be-
tween the corresponding effects. A and  represent the chip
random effect and stochastic error, respectively, and both
are assumed to be normally distributed and independent.
Indexes i, j, k, and l are associated with treatment condition,
time, chip, and probe effect, respectively. Significant genes
were determined by conducting Student’s t tests based on
the estimated parameters from this model. The specific tests
consisted of differences between treatment groups across
time (6 and 24 h) and between treatment groups within each
time period. A Bonferroni correction was applied across all
tests to control the probability of one or more false positives
to be 0.05.
Real-Time PCR Quantification
Cells were treated in the same manner as used for the har-
vesting of mRNA for the microarray screening. In some
cases, the cells were grown in 12-well plates. Cells were
lysed on the plate and total RNA was isolated using the
RNeasy mini kit (QIAGEN) with on-column deoxyribonucle-
ase digest (ribonuclease-free deoxyribonuclease set, QIA-
GEN). First-strand cDNA was prepared using 1st strand Su-
perScript II synthesis kit (Invitrogen) per manufacturer’s
instructions using random hexamer primers. Quantitative
PCR was performed using SYBR Green Supermix (Bio-Rad,
Hercules, CA) in the iCycler Real-Time PCR system (Bio-
Rad). The protocol used was as follows: 95 C for 5 min; 40
cycles of 95 C for 30 sec, 63 C for 30 sec, 72 C for 30 sec;
72 C for 7 min. Standard curves were prepared for each
primer pair and quantification was based upon the standard
curve and normalized to the housekeeping control gene
(GAPDH). Each sample was analyzed in duplicate. The se-
quences of the primers used here are as follows:
GAPDH: forward, GGCTCTCCAGAACATCATCCCTGC;
reverse, GGGTGTCGCTGTTGAAGTCAGAGG. PSA: forward,
CCTCCTGAAGAATCGATTCC; reverse, GAGGTCCACACA-
CTGAAGTT.
ABCG1: forward, CGCATCACCTCGCACATTG; reverse,
TCCCGAAGAAAGACTCCCATC
HMGCS2: forward, TCGCCTGATGTTCAATGACTTC; re-
verse, CTTGTTGGTGTAGGTGTCTTCC. SLC16A6: forward,
ACATCTTCATTCAGAGCATAGC; reverse, GTCCCATCTTA-
CACGGTCTC. FKBP51: forward, CGGAGAACCAAACGGA-
AAGG; reverse, CTTCGCCCACAGTGAATGC.
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Lipogenesis Assay
LNCaP cells were seeded in 24-well plates at 160,000 cells
per well in RPMI/8% charcoal-stripped fetal bovine serum
supplemented with nonessential amino acids and sodium
pyruvate and incubated for 3 d. Cells were induced by addi-
tion of an equal volume of the medium with 2 concentration
of hormones. After 72 h, cells were fixed in 1% formaldehyde
and stained with 0.3% Oil Red O in 60% isopropanol for 1 h.
Cells were washed with water and absorbed Oil Red O was
extracted with isopropanol. Oil Red O in extract was mea-
sured by absorbance at 490 nm. Wells with no cells in them
were treated in the same way and used as a blank. An
identical set of plates was seeded and treated in the same
way. This set was used for monitoring of cell proliferation by
direct cell counting on a Coulter counter. Accumulation of
lipids was determined as Oil Red O inclusion normalized to
cell number.
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